The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant camrelizumab plus apatinib in resectable stage II–IVA HNSCC achieved an overall major pathological response rate of 29.3% (12/41) with low grade ≥3 toxicity (2.4%).
- Why it matters: Chemotherapy-free neoadjuvant options are needed for resectable HNSCC, alongside biomarkers that link treatment to tumour microenvironment changes and pathological response.
- What they did: In a single-arm exploratory phase II trial (ChiCTR2100051989), 41 patients received one cycle (n=26) or two cycles (n=15) of camrelizumab 200 mg IV plus apatinib 250 mg orally daily for 21 days per cycle, with MPR and exploratory PD-L1 CPS, CTC clearance, and mIF profiling in 30 paired samples.
- The result: MPR was linked to PD-L1 CPS ≥20 (50.0% vs 13.0%; BH-adjusted p=0.023) and to post-neoadjuvant CTC clearance (87.5% vs 36.8%; BH-adjusted p=0.033), and mIF showed vascular normalisation, hypoxia relief, and immune reprogramming in MPR patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.